Alseres Pharmaceuticals Announces 12 Month Interim Results From The Phase I/IIa Cethr

New cases in Pous 2064, HIV = 175, AIDS = 26, Death = 2. HIV rate is very high in Housewives than sex workers in Nepal ! ! ! HIV status in Nepal till 2005: Total Adult=70000, Adult Prevalence (15-49)=0.55%, Number of Women (15-49) LWHA=15,310 (22%), HIV Prevalence rate in IDUs=32.7%, HIV prevalence rate in sex worker=3.8%, HIV prevalence rate in client of SW=2.1%. The latest U.N. report shows that 65 million people have been infected with HIV since it was first identified 25 years ago. Twenty five million people have died of AIDS.

Welcome to the xenoMED, an online Medical Community where Academically sound, Professionally conscious and Socially responsible Medical Students, Doctors & Health Professionals interact with each other globally.

Medicine is the only profession that incessantly tries to destroy its own existence. Howsoever you may be associated with basic and/or clinical medicine - student or professor, physician or surgeon, undergraduate or postgraduate - this is your place to share your knowledge, and learn more. Just get the message across!

You are currently viewing our communiy as a guest which gives you limited access to view most discussions and access our other features. By joining our free community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, Join Our Medical Cummunity Today!

If you have any problems with the registration process or your account login, please contact us.

		xenoMED > News Room > Health News > Medical News Today
Alseres Pharmaceuticals Announces 12 Month Interim Results From The Phase I/IIa Cethr

LinkBack

Thread Tools

Display Modes

(#1 (permalink))

News is Offline

Senior Member

Posts: 586

Thanks: 0

Thanked 25 Times in 25 Posts

Join Date: Sep 2007

Alseres Pharmaceuticals Announces 12 Month Interim Results From The Phase I/IIa Cethr - 13-05-2008, 01:10 AM

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced 12-month interim data from its Phase I/IIa clinical trial of Cethrin, a proprietary recombinant protein that is being investigated for its potential to restore motor and sensory function after spinal cord injury, or SCI. The trial enrolled a total of 48 patients of which 37 have reached the final 12 month follow up evaluation.

More...

Remove advertisements

Sponsored links

« Minn. House Passes Bill Clarifying That State Funds Can Be Used For Embryonic Stem Ce | MS Can Affect Children's IQ, Thinking Skills »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts vB code is On Smilies are On [IMG] code is On HTML code is Off Trackbacks are On Pingbacks are On Refbacks are On

Similar Threads
Thread	Thread Starter	Forum	Replies	Last Post
Iomai Announces Interim Results From Phase 1 Study Of Its Patch-Based Vaccine For Sea	Angel	Medical News Today	0	27-05-2007 12:30 AM
Vertex Pharmaceuticals Announces Results Of First Interim Safety And Antiviral Analys	Angel	Medical News Today	0	24-12-2006 12:10 AM
Reata Announces Presentation Of Interim Results For Phase 1 Study Of RTA 744 In Treat	Angel	Medical News Today	0	11-11-2006 12:13 AM
Poniard Announces Positive Interim Survival Results From Ongoing Phase 2 Trial Of Pic	Angel	Medical News Today	0	07-11-2006 12:13 AM

Remove advertisements

Hosted and Maintained by: